pageleftimg products
pagebanner products
imgfollow

ABV-1504  Major Depressive Disorder 

▌ Indication
    Major Depressive Disorder (MDD)

▌ MOA
    Norepinephrine Transporter (NET) inhibitor
img 1504-1

▌ Status
    2015   Phase II trial first patient recruited
    2014   IND approval for Phase II trial from US FDA, TFDA
    2012   IND approval for Phase I trial from  US FDA, TFDA

▌ Patent
    Granted in US, GB, JP, DE, FR, IT, CH, TW

 

▌ Pharmacology
    Inhibition of TBZ-induced hypothermia
img 1504-2

▌ Toxicology
    Genotoxicity: negative
    NOAEL in rats & dogs: 3000mg/kg/day

▌ Phase I
    Well-tolerated in healthy volunteers up to 3800 mg (single dose)

Copyright © American BriVision Corporation . All rights reserved. Design BY NOYAINC